biotech / news / / Barchart
Johnson & Johnson (JNJ) is a global healthcare leader dedicated to advancing medical innovation and improving patient outcomes.
Johnson & Johnson raised its fiscal 2026 guidance, projecting adjusted EPS of $11.45-$11.65.
KEY POINTS
- Q1 2024 sales grew 9.9% year-over-year to $24.1 billion, beating consensus by 2.6%.
- Despite higher sales, adjusted EPS declined 2.5% to $2.70 in Q1 but exceeded estimates.
- Johnson & Johnson has outperformed both the S&P 500 and XLV over the past 52 weeks.
- The consensus analyst price target of $259.92 implies a 14.7% upside from current levels.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →